Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) J Natl Cancer Inst 104: 1264; author reply 1266-8 Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. Goetz MP, Brauch H, Ratain MJ, Cox NJ, Nakamura Y, Weinshilboum R, Ingle JN (2014) J Natl Cancer Inst 106: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R (2014) J Natl Cancer Inst 107: Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA, Branch RA (1987) Cancer Res 47: 5488-93 CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Ratain MJ, Nakamura Y, Cox NJ (2013) Clin Pharmacol Ther 94: 185-7 Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Fang H, Liu X, Ramírez J, Choudhury N, Kubo M, Im HK, Konkashbaev A, Cox NJ, Ratain MJ, Nakamura Y, O'Donnell PH (2014) Pharmacogenomics J 14: 564-72 Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. Hanna IH, Krauser JA, Cai H, Kim MS, Guengerich FP (2001) J Biol Chem 276: 39553-61 Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. Guengerich FP, Miller GP, Hanna IH, Sato H, Martin MV (2002) J Biol Chem 277: 33711-9 Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models. Chattopadhyay M, Chowdhury AR, Feng T, Assenmacher CA, Radaelli E, Guengerich FP, Avadhani NG (2019) J Biol Chem 294: 10336-10348 Mammalian cytochrome P450 enzymes catalyze the phenol-coupling step in endogenous morphine biosynthesis. Grobe N, Zhang B, Fisinger U, Kutchan TM, Zenk MH, Guengerich FP (2009) J Biol Chem 284: 24425-31 Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes. Guengerich FP, Wilkey CJ, Phan TTN (2019) J Biol Chem 294: 10928-10941 Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. Bajpai P, Sangar MC, Singh S, Tang W, Bansal S, Chowdhury G, Cheng Q, Fang JK, Martin MV, Guengerich FP, Avadhani NG (2013) J Biol Chem 288: 4436-51 Genetic polymorphism of CYP2D6 and lung cancer risk. Shaw GL, Falk RT, Frame JN, Weiffenbach B, Nesbitt JC, Pass HI, Caporaso NE, Moir DT, Tucker MA (1998) Cancer Epidemiol Biomarkers Prev 7: 215-9 Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism. Sangar MC, Anandatheerthavarada HK, Tang W, Prabu SK, Martin MV, Dostalek M, Guengerich FP, Avadhani NG (2009) FEBS J 276: 3440-53 Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Oetjens MT, Denny JC, Ritchie MD, Gillani NB, Richardson DM, Restrepo NA, Pulley JM, Dilks HH, Basford MA, Bowton E, Masys DR, Wilke RA, Roden DM, Crawford DC (2013) Pharmacogenomics 14: 735-44 Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Guengerich FP, Hanna IH, Martin MV, Gillam EM (2003) Biochemistry 42: 1245-53 Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Miller GP, Hanna IH, Nishimura Y, Guengerich FP (2001) Biochemistry 40: 14215-23 Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Guengerich FP, Miller GP, Hanna IH, Martin MV, Léger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, Nicoll-Griffith DA (2002) Biochemistry 41: 11025-34 Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Hanna IH, Kim MS, Guengerich FP (2001) Arch Biochem Biophys 393: 255-61 Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Caraco Y, Tateishi T, Guengerich FP, Wood AJ (1996) Drug Metab Dispos 24: 761-4 Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. Sangar MC, Anandatheerthavarada HK, Martin MV, Guengerich FP, Avadhani NG (2010) Mol Genet Metab 99: 90-7 Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Anthony LB, Boeve TJ, Hande KR (1995) Cancer Chemother Pharmacol 36: 125-8 CYP2D6 genotype and adverse events to risperidone in children and adolescents. Oshikoya KA, Neely KM, Carroll RJ, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL (2019) Pediatr Res 85: 602-606 Coumarin substrates for cytochrome P450 2D6 fluorescence assays. Nakamura K, Hanna IH, Cai H, Nishimura Y, Williams KM, Guengerich FP (2001) Anal Biochem 292: 280-6 Purification of functional recombinant P450s from bacteria. Guengerich FP, Martin MV, Guo Z, Chun YJ (1996) Methods Enzymol 272: 35-44
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.